Literature DB >> 36042691

Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4-6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo.

Blerim Myftiu1,2, Zylfije Hundozi1,2, Faton Sermaxhaj3, Afrim Blyta1, Nexhmedin Shala1,2, Fisnik Jashari1,2, Hasime Qorraj Bytyqi4, Ekrem Hyseni3, Ilir Kurtishi3.   

Abstract

BACKGROUND Chemotherapy-induced peripheral neuropathy (CIPN) is most commonly associated with platinum-based drugs, taxanes, and vinca alkaloids. This prospective study from a single center in Kosovo aimed to evaluate CIPN in 120 patients receiving 4-6 cycles of platinum-based and taxane-based chemotherapy. MATERIAL AND METHODS One hundred twenty patients underwent neurological examination and nerve conduction studies (NCS) before chemotherapy, and after 4 to 6 cycles of treatment. Sixty patients were treated with platinum-based chemotherapy, 30 were treated with taxane-based chemotherapy, and 22 patients received a combination of platinum- and taxane-based chemotherapy. The most commonly used platinum-based compounds were oxaliplatin and carboplatin, whereas the most commonly used taxane medications were paclitaxel and docetaxel. Presence of neuropathy was confirmed with neurological examination of electrophysiological criteria applicable for polyneuropathies. Total Neuropathy Score (TNSr) was used to combine clinical and electrophysiological values. RESULTS Around 90% of patients self-reported neuropathic symptoms, and in 60% of them polyneuropathy was present in NCS. All sensory and motor nerves had significantly lower amplitudes (P<0.01). Platinum-based agents caused more pronounced decrease in ulnar nerve compound motor action potential (CMAP) (P<0.05); when used solely or in combination with taxanes, they caused significant decrease in tibial nerve CMAP (P<0.01). TNSr did not reach statistical significance between groups; only clinical muscle strength showed pronounced weakness in the combined protocol (P<0.05). CONCLUSIONS These findings support previous studies and show that CIPN, including sensory and motor symptoms, is commonly associated with chemotherapy. Platinum-based chemotherapy agents were more commonly associated with ulnar and tibial nerve damage in this study population.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36042691      PMCID: PMC9443419          DOI: 10.12659/MSM.937856

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  38 in total

1.  Toxic neuropathy in patients with pre-existing neuropathy.

Authors:  V Chaudhry; M Chaudhry; T O Crawford; E Simmons-O'Brien; J W Griffin
Journal:  Neurology       Date:  2003-01-28       Impact factor: 9.910

2.  High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.

Authors:  S R Patel; S Vadhan-Raj; N Papadopolous; C Plager; M A Burgess; C Hays; R S Benjamin
Journal:  J Clin Oncol       Date:  1997-06       Impact factor: 44.544

Review 3.  Chemotherapy-induced peripheral neuropathy - epidemiology and pathogenesis.

Authors:  Dariusz Iżycki; Adam Niezgoda; Maciej Kaźmierczak; Ewa Nowak-Markwitz
Journal:  Ginekol Pol       Date:  2016       Impact factor: 1.232

4.  Inhibition of axoplasmic transport by colchicine, podophyllotoxin, and vinblastine: an effect on microtubules.

Authors:  J C Paulson; W O McClure
Journal:  Ann N Y Acad Sci       Date:  1975-06-30       Impact factor: 5.691

5.  Oxaliplatin-induced neurotoxicity and the development of neuropathy.

Authors:  Arun V Krishnan; David Goldstein; Michael Friedlander; Matthew C Kiernan
Journal:  Muscle Nerve       Date:  2005-07       Impact factor: 3.217

Review 6.  Chemotherapy-induced neuropathy.

Authors:  Anthony J Windebank; Wolfgang Grisold
Journal:  J Peripher Nerv Syst       Date:  2008-03       Impact factor: 3.494

7.  Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients.

Authors:  Roser Velasco; Jordi Bruna; Chiara Briani; Andreas A Argyriou; Guido Cavaletti; Paola Alberti; Barbara Frigeni; Mario Cacciavillani; Sara Lonardi; Diego Cortinovis; Marina Cazzaniga; Cristina Santos; Haralabos P Kalofonos
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-06-29       Impact factor: 10.154

8.  Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study.

Authors:  G Cavaletti; A Beronio; L Reni; E Ghiglione; A Schenone; C Briani; G Zara; D Cocito; G Isoardo; P Ciaramitaro; R Plasmati; F Pastorelli; M Frigo; M Piatti; M Carpo
Journal:  Neurology       Date:  2004-06-22       Impact factor: 9.910

9.  Chemotherapy-induced polyneuropathy. Part I. Pathophysiology.

Authors:  Krzysztof Brzeziński
Journal:  Contemp Oncol (Pozn)       Date:  2012-02-29

10.  Timed Vibration Sense and Joint Position Sense Testing in the Diagnosis of Distal Sensory Polyneuropathy.

Authors:  Appaswamy Thirumal Prabhakar; Tharan Suresh; Dilu Susan Kurian; Vivek Mathew; Atif Iqbal Ahmed Shaik; Sanjith Aaron; Ajith Sivadasan; Rohit Ninan Benjamin; Mathew Alexander
Journal:  J Neurosci Rural Pract       Date:  2019 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.